Rectal Temperature: A Game-Changer in Diagnosing Intrapartum Infections

Rectal Temperature: A Game-Changer in Diagnosing Intrapartum Infections

A recent letter published in the American Journal of Obstetrics & Gynecology highlights the critical role of rectal temperature measurement in improving the diagnosis of intrapartum infections. While oral temperature measurements are commonly used, they often underestimate core body temperature, potentially delaying the diagnosis of conditions like chorioamnionitis.
A New Year, A New Chapter in Hematology

A New Year, A New Chapter in Hematology

As we step into 2025, we reflect on the incredible progress made in hematology and set our sights on the breakthroughs to come. This heartfelt message celebrates the dedication of our doctors, researchers, and patients who inspire hope and innovation every day. Let’s work hand in hand to bring new solutions, brighter outcomes, and life-changing treatments to patients worldwide. Together, we can push the boundaries of medicine and create miracles in hematology. Watch this inspiring New Year message as we welcome a year of health, happiness, and progress. Let’s embrace 2025 with hope and determination!
93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest global academic event in the field of hematology, took place from December 7 to 10, 2024, in San Diego, USA. The event brought  together leading researchers and clinicians from around the world to discuss cutting-edge advancements in hematology, innovative therapies, and ongoing clinical trials.Following rigorous peer review, 10 high-quality abstracts from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected for oral presentations, and an additional 83 abstracts were featured in poster sessions.
N Engl J Med | Professors Lei Zhang and Renchi Yang’s Team Unveils Efficacy, Safety, and Mechanism of a Novel CD38 Monoclonal Antibody in ITP Patients

N Engl J Med | Professors Lei Zhang and Renchi Yang’s Team Unveils Efficacy, Safety, and Mechanism of a Novel CD38 Monoclonal Antibody in ITP Patients

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production due to antibody-mediated mechanisms. Current first-line therapies for ITP include glucocorticoids and immunoglobulins, while second-line options often involve thrombopoietin receptor agonists (TPO-RAs), CD20 monoclonal antibodies, and splenectomy. The introduction of CD20 monoclonal antibody therapy over the past decade has transformed ITP treatment. However, heterogeneity in treatment response and duration leaves a subset of patients at risk of severe bleeding, reduced quality of life, and increased mortality. Following the success of CD20 antibodies, researchers have been exploring other potent therapeutic targets to address these unmet needs.
Leukemia | Professors Junren Chen, Erlie Jiang, Zimin Sun’s Team Validates New Standard for Calculating CD34+ Cell Dose

Leukemia | Professors Junren Chen, Erlie Jiang, Zimin Sun’s Team Validates New Standard for Calculating CD34+ Cell Dose

Recently, the team led by Professor Junren Chen from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, along with Professor Zimin Sun’s team from The First Affiliated Hospital of the University of Science and Technology of China, conducted a retrospective analysis of 620 unrelated cord blood transplant cases in Anhui.
JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore methods to enhance the efficacy of CAR-T therapy.